{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:31:00Z","timestamp":1787020260499,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although antifibrotic drugs, including nintedanib and pirfenidone, slow the progression of idiopathic pulmonary fibrosis (IPF), there is little data about the timing of start of antifibrotic treatment in real-world clinical practice. The present study aimed to clarify the efficacy of nintedanib and pirfenidone in patients with early-stage IPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compared survival and disease progression between patients with IPF with Japanese Respiratory Society (JRS) disease severity system stage I with and without oxygen desaturation on the 6-min walk test (6MWT) and increased the gender\u2013age\u2013physiology (GAP) staging. We examined the efficacy of antifibrotic drugs in patients with early-stage IPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The severity of stage I IPF (n\u2009=\u2009179) according to the JRS criteria consisted of the following GAP staging criteria: stage I, 111 cases; stage II, 58 cases; stage III, 10 cases. The duration from the initial visit to disease progression and survival time was significantly shorter in JRS stage I patients with oxygen desaturation on the 6MWT or with increased GAP staging (unfavorable group) compared with patients without those factors. In the unfavorable group, the relative decline in percentage predicted forced vital capacity (%FVC) over 6\u00a0months was significantly lower in patients undergoing antifibrotic treatment compared with non-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Antifibrotic drugs have a beneficial effect on the decline in %FVC in Japanese patients with early-stage IPF who have oxygen desaturation on the 6MWT or increased GAP staging.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-021-01595-3","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T02:03:16Z","timestamp":1625882596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis"],"prefix":"10.1186","volume":"21","author":[{"given":"Keishi","family":"Sugino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiyasu","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakae","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,10]]},"reference":[{"key":"1595_CR1","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"key":"1595_CR2","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","volume":"378","author":"TE King Jr","year":"2011","unstructured":"King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949\u201361.","journal-title":"Lancet"},{"key":"1595_CR3","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"1595_CR4","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083\u201392.","journal-title":"N Engl J Med"},{"issue":"2","key":"1595_CR5","doi-asserted-by":"publisher","first-page":"1601592","DOI":"10.1183\/13993003.01592-2016","volume":"49","author":"HE Jo","year":"2017","unstructured":"Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PM, Moodley Y, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J. 2017;49(2):1601592.","journal-title":"Eur Respir J"},{"issue":"1","key":"1595_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12931-018-0845-5","volume":"19","author":"A Guenther","year":"2018","unstructured":"Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):141.","journal-title":"Respir Res"},{"key":"1595_CR7","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1183\/09031936.00155108","volume":"35","author":"CJ Zappala","year":"2010","unstructured":"Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:830\u20136.","journal-title":"Eur Respir J"},{"key":"1595_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1164\/rccm.200211-1311OC","volume":"168","author":"HR Collard","year":"2003","unstructured":"Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538\u201342.","journal-title":"Am J Respir Crit Care Med"},{"key":"1595_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1164\/rccm.200209-1112OC","volume":"168","author":"KR Flaherty","year":"2003","unstructured":"Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:543\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"1595_CR10","doi-asserted-by":"publisher","first-page":"170053","DOI":"10.1183\/16000617.0053-2017","volume":"26","author":"SE Torrisi","year":"2017","unstructured":"Torrisi SE, Pavone M, Vancheri A, Vancheri C. When to start and when to stop antifibrotic therapies. Eur Respir Rev. 2017;26:170053.","journal-title":"Eur Respir Rev"},{"key":"1595_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.resinv.2014.08.003","volume":"53","author":"S Homma","year":"2015","unstructured":"Homma S, Sugino K, Sakamoto S. Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. Respir Investig. 2015;53:7\u201312.","journal-title":"Respir Investig"},{"key":"1595_CR12","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156:684\u201391.","journal-title":"Ann Intern Med"},{"key":"1595_CR13","doi-asserted-by":"publisher","first-page":"00127","DOI":"10.1183\/23120541.00127-2018","volume":"5","author":"CJ Ryerson","year":"2019","unstructured":"Ryerson CJ, Kolb M, Richeldi L, Lee J, Wachtlin D, Stowasser S, et al. Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Res. 2019;5:00127\u20132018.","journal-title":"ERJ Open Res"},{"key":"1595_CR14","first-page":"129","volume":"32","author":"K Sugino","year":"2015","unstructured":"Sugino K, Nakamura Y, Ito T, Isshiki T, Sakamoto S, Homma S. Comparison of clinical characteristics and outcomes between combined pulmonary fibrosis and emphysema associated with usual interstitial pneumonia pattern and non-usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32:129\u201337.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"1595_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1378\/chest.12-2403","volume":"144","author":"CJ Ryerson","year":"2013","unstructured":"Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013;144:234\u201340.","journal-title":"Chest"},{"key":"1595_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194:265\u201375.","journal-title":"Am J Respir Crit Care Med"},{"key":"1595_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","unstructured":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1595_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12931-019-1161-4","volume":"20","author":"TM Maher","year":"2019","unstructured":"Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019;20:205.","journal-title":"Respir Res"},{"key":"1595_CR19","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/resp.13138","volume":"22","author":"Y Kondoh","year":"2017","unstructured":"Kondoh Y, Taniguchi H, Kataoka K, Furukawa T, Ando M, Murotani K, et al. Disease severity staging system for idiopathic pulmonary fibrosis in Japan. Respirology. 2017;22:1609\u201314.","journal-title":"Respirology"},{"key":"1595_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1378\/chest.14-0453","volume":"147","author":"ES Kim","year":"2015","unstructured":"Kim ES, Choi SM, Lee J, Park YS, Lee CH, Yim JJ, et al. Validation of the GAP score in Korean patients with idiopathic pulmonary fibrosis. Chest. 2015;147:430\u20137.","journal-title":"Chest"},{"key":"1595_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.resinv.2016.02.009","volume":"54","author":"S Kondoh","year":"2016","unstructured":"Kondoh S, Chiba H, Nishikiori H, Umeda Y, Kuronuma K, Otsuka M, et al. Validation of the Japanese disease severity classification and the GAP model in Japanese patients with idiopathic pulmonary fibrosis. Respir Investig. 2016;54:327\u201333.","journal-title":"Respir Investig"},{"key":"1595_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/thoraxjnl-2016-208710","volume":"72","author":"M Kolb","year":"2017","unstructured":"Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72:340\u20136.","journal-title":"Thorax"},{"key":"1595_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1183\/13993003.01966-2015","volume":"48","author":"C Albera","year":"2016","unstructured":"Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016;48:843\u201351.","journal-title":"Eur Respir J"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01595-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-021-01595-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01595-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T02:03:45Z","timestamp":1625882625000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-021-01595-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,10]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1595"],"URL":"https:\/\/doi.org\/10.1186\/s12890-021-01595-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-139548\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-139548\/v2","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,10]]},"assertion":[{"value":"4 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Tsuboi Hospital (No. Zizan 1\u20133). The Ethical Committees of Tsuboi Hospital waived the need for informed consent because of the retrospective clinical review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors contributed substantially to this work and are responsible for the consent of the manuscript. SH is a member of an endowed department sponsored by Teijin Pharma, Co., Ltd., Nippon Boehringer Ingelheim, Co., Ltd., Shionogi & Co., Ltd., and Chugai Pharmaceutical Co., Ltd. SH, KK, and KS have received lecture fees from Nippon Boehringer Ingelheim Co., Ltd. KK has received research funding from Nippon Boehringer Ingelheim Co., Ltd. The other authors have no financial relationships relevant to this article. All authors have no competing non-financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"218"}}